---
title: "Belite Bio, Inc (BLTE.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/BLTE.US.md"
symbol: "BLTE.US"
name: "Belite Bio, Inc"
industry: "Pharmaceuticals"
---

# Belite Bio, Inc (BLTE.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [www.belitebio.com](https://www.belitebio.com) |

## Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally admini...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -105.39 | 224/256 | - | - | - |
| PB | 23.99 | 185/256 | 20.70 | 14.93 | 12.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-28T05:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 75% |
| Overweight | 2 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 175.26 |
| Highest Target | 200.00 |
| Lowest Target | 185.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/BLTE.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/BLTE.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/BLTE.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.